Treatment decisions for MRSA in patients with cystic fibrosis (CF): when is enough, enough?

Scott C Bell^{1

2}, Patrick A Flume³

Affiliations

¹ QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
² Department of Thoracic Medicine, The Prince Charles Hospital, Brisbane, Queensland, Australia.
³ Departments of Medicine and Pediatrics, Medical University of South Carolina, Charleston, South Carolina, USA.

Editorial

Scott C Bell et al. Thorax. 2017 Apr.

. 2017 Apr;72(4):297-299.

doi: 10.1136/thoraxjnl-2016-209605. Epub 2017 Jan 11.

Scott C Bell^{1

2}, Patrick A Flume³

¹ QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
² Department of Thoracic Medicine, The Prince Charles Hospital, Brisbane, Queensland, Australia.
³ Departments of Medicine and Pediatrics, Medical University of South Carolina, Charleston, South Carolina, USA.

No abstract available

Keywords: Cystic Fibrosis; Respiratory Infection.

Comment on

Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trial.
Muhlebach MS, Beckett V, Popowitch E, Miller MB, Baines A, Mayer-Hamblett N, Zemanick ET, Hoover WC, VanDalfsen JM, Campbell P, Goss CH; STAR-too study team. Muhlebach MS, et al. Thorax. 2017 Apr;72(4):318-326. doi: 10.1136/thoraxjnl-2016-208949. Epub 2016 Nov 15. Thorax. 2017. PMID: 27852955 Free PMC article.